iCRYO NAD+ review

The schedule is the main tradeoff

iCRYO’s strongest practical feature is a clearly separated menu of NAD+ IV infusions and IM shots. Its biggest tradeoff is the proposed schedule. The page lists infusion service times of one to six hours and shot appointments of about ten minutes. ^[1] Those are very different purchases in terms of effort. A reader attracted by an energy promise should first decide how much supervised appointment time is realistic. The longer option is not automatically the more effective one, and a brief appointment does not remove the need for a sensible clinical explanation.

Two routes mean two comparisons

The published IV options span 250 to 1,000 mg, while the IM options list 100 and 200 mg. ^[1] Keep the unit and route together when comparing them. An injection amount cannot be ranked against an infusion amount as though both were the same type of serving. Ask which preparation is proposed and how the team explains the choice. The small human infusion pilot measured blood and urine chemistry rather than comparing these commercial options. ^[2] It cannot decide which iCRYO visit will produce the best functional result for an individual reader.

A loading plan is a proposal

iCRYO describes loading either through five consecutive days or once weekly over five weeks, followed by a proposed maintenance schedule. ^[1] That is a substantial program. I would want a clear rationale and a reassessment point before paying for it, especially if several visits must be purchased together. The label loading gives the schedule a medical sound, but it does not itself prove that the particular sequence improves a patient-important outcome. The decision should remain open to a smaller commitment or no treatment if the clinical purpose is not persuasive.

Keep the clinical claim in perspective with what human NAD infusion research measures.

Time belongs beside the price

A multi-visit quote should make both cash and time visible. Include the expected visit length, travel and any assessment charge rather than comparing only the treatment amount. Establish the consequence of a missed appointment, a change in health or an infusion that must be stopped early. Those conditions can change value more than a small discount. Someone with limited flexibility may reasonably prefer a single supervised discussion rather than a predetermined series. The most useful financial protection is an understandable agreement, not a promise that the program will eventually pay for itself through better energy.

Natural does not settle safety

The website’s natural-molecule framing should not be used as a general safety guarantee. ^[1] A substance that participates in normal biology can still raise questions when prepared and administered through a particular route. FDA has highlighted risks from unsuitable ingredients used in sterile compounding, including NAD-related products; that is a general warning, not a finding about iCRYO. ^[3] Ask who supplies the actual preparation and who makes the clinical decision. An answer about experienced staff is useful, but it should accompany an explanation of the treatment rather than replace it.

Keep the expected benefit specific

I would be especially cautious about interpreting slower-aging language as an established result of a series of infusions. The Grant study was a metabolism pilot, not a longevity trial. ^[2] Energy, focus, recovery and lifespan are different outcomes requiring different evidence. The clinician should be able to narrow the discussion to a specific purpose and acknowledge what remains uncertain. A reader does not need to choose between promotional enthusiasm and rejecting all research. It is reasonable to remain interested while refusing to treat an untested broad promise as a purchasing fact.

My buying judgment

iCRYO can be a workable local option for someone who deliberately prefers supervised administration and understands the proposed schedule. I would prioritize clear preparation details and flexible reassessment over the largest dose or most intensive loading sequence. Get the full series cost and cancellation conditions before enrolling. Then compare the appointment burden with another clinic or a different delivery model, keeping the evidence limits attached. The menu is easy to navigate; the important decision is whether the clinical case and the ongoing commitment are equally easy to understand.

For a different delivery model, read our AgelessRx review before choosing a route.

Understanding the cost

Obtain a selected-service quote including required assessment, supplied treatment and recurring or cancellation terms.